Editorial
Colorectal cancer: a multifaceted disease
Chinese Clinical Oncology
2019;
8
(5)
:45
.
(09 October 2019)
Original Article
The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases
Chinese Clinical Oncology
2019;
8
(5)
:46
.
(09 October 2019)
Review Article
Japanese experience with hepatic resection of KRAS-mutated colorectal liver metastases
Chinese Clinical Oncology
2019;
8
(5)
:47
.
(09 October 2019)
Limitations of molecular biomarkers in patients with resectable colorectal liver metastases
Chinese Clinical Oncology
2019;
8
(5)
:48
.
(09 October 2019)
Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer
Chinese Clinical Oncology
2019;
8
(5)
:49
.
(09 October 2019)
Interactions of multiple gene alterations in colorectal liver metastases
Chinese Clinical Oncology
2019;
8
(5)
:50
.
(09 October 2019)
Tailoring ablation strategies for colorectal liver metastases based upon rat sarcoma viral oncogene mutation status
Chinese Clinical Oncology
2019;
8
(5)
:51
.
(09 October 2019)
The impact of somatic SMAD4 mutations in colorectal liver metastases
Chinese Clinical Oncology
2019;
8
(5)
:52
.
(09 October 2019)
Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer
Chinese Clinical Oncology
2019;
8
(5)
:53
.
(09 October 2019)
The state of hepatic artery infusion chemotherapy in the management of metastatic colorectal cancer to the liver
Chinese Clinical Oncology
2019;
8
(5)
:54
.
(09 October 2019)
RAS mutation: site of disease and recurrence pattern in colorectal cancer
Chinese Clinical Oncology
2019;
8
(5)
:55
.
(09 October 2019)
Disclosure:
The focused issue “Molecular Markers in Colorectal Cancer” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Yun Shin Chun and Michael D’Angelica served as the unpaid Guest Editors for the focused issue.